London-based healthcare investment firm Apposite Capital has joined the $10.5 million (£6.5 million) series C venture funding of Ulthera.

London-based healthcare investment firm Apposite Capital has joined the $10.5 million (£6.5 million) series C venture funding of Ulthera.

Privately held Ulthera, which is located in Arizona, US, is the developer of what the company claims is the first-ever ultrasound device approved by the US Food and Drug Administration for cosmetic surgery. The non-invasive technology uses ultrasound therapy to lift and tone the skin, according to Ulthera.

Californian venture capital firm New Enterprise Associates led the round with participation by funds managed by Apposite Capital, a statement from Apposite says.

Ulthera president and chief executive Matthew Likens adds the fundraising will enable the business to develop new clinical applications, invest in product development and hire more staff.

The technology has been available in Europe and Asia since 2008, and across the US since late 2009. The company was founded in 2004.